NCT05327595

A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM)

A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3549492 in Patients With Type 2 Diabetes Mellitus

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in participants with T2DM. Blood tests will be done to check how much LY3549492 gets into the bloodstream and how the body handles LY3549492. This study has two parts. Each participant will enroll in only one part. The study will last either 12 or 13 weeks, depending on part.

Conditions

• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	LY3549492	Administered orally.
DRUG	Placebo	Administered orally.
DRUG	Atorvastatin	Administered orally.
DRUG	Midazolam	Administered orally.

Timeline

• Start date: 2022-05-09
• Primary completion: 2024-04-22
• Completion: 2024-04-22
• First posted: 2022-04-14
• Last updated: 2024-05-30

Locations

1 site across 1 country: Germany

Regulatory

• FDA-regulated drug study